Table 1 Baseline characteristics before and after propensity score matching for control versus 5-flurouracil and capecitabine
Before propensity score matching | After propensity score matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|  | Combined n = 51,888 | Control n = 41,274 | 5-flurouracil & capecitabine n = 10,614 | SMD | p value | Combined n = 21,216 | Control n = 10,608 | 5-flurouracil & capecitabine n = 10,608 | SMD |
Sex(female), n(%) | 2,347(45.2%) | 18,984(46%) | 4,492(42.3%) | -0.07 | < 0.001* | 8,794(41.4%) | 4,302(40.6%) | 4,492(42.3%) | 0.04 |
Age(years), mean ± SD | 69.9+/-12.8 | 72+/-12.4 | 61.8+/-10.9 | -0.94 | < 0.001* | 61.9+/-11.2 | 62+/-11.6 | 61.8+/-10.9 | -0.02 |
Hypertension, n(%) | 18,004(34.7%) | 14,733(35.7%) | 3,271(30.8%) | -0.11 | 0.001* | 6,416(30.2%) | 3,145(29.6%) | 3,271(30.8%) | 0.03 |
Diabetes mellitus, n(%) | 9,012(17.4%) | 7,430(18%) | 1,582(14.9%) | -0.09 | < 0.001* | 3,151(14.9%) | 1,569(14.8%) | 1,582(14.9%) | 0.01 |
Chronic kidney disease, n(%) | 987(1.90%) | 972(2.35%) | 15(0.14%) | -0.59 | < 0.001* | 25(0.12%) | 10(0.09%) | 15(0.14%) | 0.01 |
Atrial fibrillation, n(%) | 2,474(4.77%) | 2,281(5.53%) | 193(1.82%) | -0.28 | < 0.001* | 310(1.46%) | 117(1.10%) | 193(1.82%) | 0.05 |
Myocardial infarction, n(%)# | 1,033(1.99%) | 942(2.28%) | 91(0.86%) | -0.15 | < 0.001* | 148(0.70%) | 57(0.54%) | 91(0.86%) | 0.03 |
Ischemic stroke, n(%) | 2,917(5.62%) | 2,699(6.54%) | 218(2.05%) | -0.32 | < 0.001* | 346(1.63%) | 129(1.22%) | 217(2.05%) | 0.06 |
Heart failure hospitalization, n(%) | 2,137(4.12%) | 2,062(5%) | 75(0.71%) | -0.51 | < 0.001* | 112(0.52%) | 37(0.35%) | 75(0.71%) | 0.04 |
Deep vein thrombosis, n(%) | 508(0.97%) | 450(1.09%) | 58(0.55%) | -0.07 | < 0.001* | 103(0.48%) | 45(0.42%) | 58(0.55%) | 0.02 |
Pulmonary embolism, n(%) | 244(0.47%) | 199(0.482%) | 45(0.42%) | -0.01 | 0.47 | 85(0.40%) | 40(0.38%) | 45(0.42%) | 0.01 |